Program
Dacarbazine
Also written as “dacarbazine”, “Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)” and “dacarbazine plus Genasense”.
Its studies are mostly in Melanoma · Hodgkin Disease · Sarcoma, Alveolar Soft Part, led by Bayer.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayer | 10 open or running | phase 2since Jun 26, 2007 | Jun 26, 2007 | none ahead |
Also a collaborator on its studies: medarex and kudos-pharmaceuticals-limited.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 26, 2007First study: phase 2 study in MelanomaFirst studyNCT00492297 · 83 enrolled · France, United Kingdom
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00492297Melanoma · France, United Kingdom | 2 | Completed | Jun 2008 | 83 |
How it is read
Names in the registry
- “Dacarbazine”, 8 entries
- “dacarbazine”, 3 entries
- “Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)”, 1 entry
- “dacarbazine plus Genasense”, 1 entry
- “Dacarbazine + Interferon alpha + Thymosin-alpha-1 1.6 mg”, 1 entry
Conditions, from the studies’ own filings
- Melanoma, 11 studies
- Hodgkin Disease, 2 studies
- Sarcoma, Alveolar Soft Part, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.